Medicine :   
Nefazodone is a Medicine belongs to group whose properties about Brand can be referenced from   Book : Martindale    Page : 444   Edition : 37,

  ►   Brandname : Nefadon

  ►  Doseform : with 50  , with 100  , with 150  , with 200  , with 250  ,

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 539   Edition : 12,
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral,
Reference :-   Book : Martindale    Page : 444   Edition : 37,

  ►  Indication/uses : depression,
Reference :-   Book : Martindale    Page : 444   Edition : 37,
Dosing of Medicine differ in Adult & Pediatrics ↓

► Nefazodone medicine for Adults :

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage   Frequency   Additional Info
1 Depression Oral 100 mg Tablet b.d. Dose increased if necessary, in increments of 100 to 200 mg at intervals of at least a week, to a maximum of 300 mg twice daily. Doses are restricted in elderly patients: a recommended initial dose is 50 mg twice daily.

Ref :-  Book : Martindale    Page : 444   Edition : 37,

For Pediatric :
S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage   Additional Info  

Ref :- Book :    Page :    Edition : ,
►  Side Effect : weakness, dry mouth, nausea, constipation, Somnolence, Dizziness, insomnia, lightheadedness, chills, fever, Orthostatic hypotension, incoordination, vasodilatation, arthralgia, paraesthesia, Confusion, memory impairment, abnormal dreams, ataxia, amblyopia, visual disturbances, hepatotoxicity, ,
Ref :-   Book : Martindale    Page : 443   Edition : 37,

►  Interaction : , Phenelzine, , Astemizole, Cisapride , Pimozide , Terfenadine, Atorvastatin , Lovastatin , Simvastatin , , Tacrolimus , , Digoxin , Haloperidol , Carbamazapine , Buspirone , ,
Ref :-   Book : Martindale    Page : 444   Edition : 37,

►  Contraindication : Treatment with nefazodone should not generally be started in patients with active hepatic disease or elevated baseline serum transaminases, Patients who develop signs or symptoms of hepatic impairment such as jaundice, anorexia, abdominal pain, elevated transaminase levels, or malaise during treatment should be evaluated for hepatic damage and the drug withdrawn if necessary., Nefazodone is contra-indicated in patients previously withdrawn from the drug because of hepatotoxicity., Nefazodone should be used with caution in patients with epilepsy, or a history of hypomania or mania. It should also be used with caution in cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (for example recent history of myocardial infarction, unstable heart disease, angina, or ischaemic stroke), and in any condition such as dehydration or hypovolaemia that may predispose patients to hypotension., Suicidal thoughts and behaviour may also develop during early treatment with antidepressants for other disorders; the same precautions observed when treating patients with depression should therefore be followed when treating patients with other disorders., Nefazodone may impair performance of skilled tasks and, if affected, patients should not drive or operate machinery.,
Ref :-   Book : Martindale    Page : 443   Edition : 37,
  ►    Mechanism of Drug Drug Interaction :  Nefazodone should not be given to patients receiving MAOIs or for at least 14 days after they are stopped; it has also been recommended that any drug liable to provoke a serious reaction (e.g. phenelzine) should not be given within one week of stopping nefazodone therapy. Nefazodone is an inhibitor of the cytochrome P450 isoenzyme CYP3A4 responsible for the metabolism of some benzodiazepines, and consequently it may produce clinically important increases in their plasma concentrations. Use with astemizole, cisapride, pimozide, and terfenadine (which are metabolised by the same isoenzyme) is best avoided because the potential also exists for increased plasma concentrations of these drugs, with the risk of inducing ventricular arrhythmias. Other substrates for this isoenzyme may also interact with nefazodone: atorvastatin, lovastatin, and simvastatin should be used with caution with nefazodone since there have been rare reports of rhabdomyolysis with such combinations. Increased serum concentrations of ciclosporin or tacrolimus, both substrates for CYP3A4, have been reported in patients also receiving nefazodone. Monitoring of serum ciclosporin or tacrolimus levels is recommended when either of these two drugs is given with nefazodone. Use of the vasopressin V2- receptor antagonist tolvaptan with nefazodone is contra-indicated. Plasma concentrations of digoxin are increased by nefazodone, and because of digoxin’s narrow therapeutic index, plasma concentrations of digoxin should be monitored if use with nefazodone is necessary. Caution should be exercised when haloperidol is given with nefazodone as the clearance of haloperidol may be reduced. Plasma concentrations of carbamazepine are also increased when used with nefazodone. More importantly, carbamazepine may reduce nefazodone plasma concentrations to subtherapeutic levels and therefore use together is not recommended. Giving buspirone with nefazodone significantly increases the serum concentrations of buspirone; the manufacturers of nefazodone recommend that the initial dose of buspirone is reduced if these drugs are given together. The potential for interaction between nefazodone and general anaesthetics exists and the manufacturer recommends that nefazodone should be stopped before elective surgery for as long as clinically feasible. ,
Ref :-   Book : Martindale    Page : 444   Edition : 37,

  ►  Mechanism of Action :   Nefazodone is a phenylpiperazine antidepressant. It blocks the reuptake of serotonin at presynaptic neurones and is an antagonist at postsynaptic 5- HT2 receptors. Nefazodone inhibits the reuptake of noradrenaline. It blocks α1-adrenoceptors but has no apparent effect on dopamine receptors. Nefazodone does not appear to have very significant antimuscarinic properties compared with tricyclic antidepressants.,
Ref :-   Book : Martindale    Page : 444   Edition : 37,

Dietary Products that produce same effect as  Nefazodone

►   Route of Elimination :   Hepatic (Metabolism), Renal, Faecal,
Ref :-   Book : Martindale    Page : 444   Edition : 37,

►    Plasma Half-life :   Min value :-   2 hours,    Max value :-   4 hours,
Ref :-   Book : Martindale    Page : 444   Edition : 37,

►    Peak Plasma Concentration :   Min value :-   2 hours,    Max value :-   NA
Ref :-   Book : Martindale    Page : 444   Edition : 37,